XFOR, US98420X2027

X4 Pharmaceuticals stock: Chairman Adam Craig buys 4,600 shares of X4 Pharmaceuticals stock

Published on 10/24/2026 at 00:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

A 4,600-share purchase by Adam Craig was disclosed for October 16, 2026. The October 29 investor day will update the 4WARD trial for X4 Pharmaceuticals stock.

Capital and clinical milestones

Adam Craig purchased 4,600 shares on October 16, 2026.
X4 secured up to USD 150 million on October 8, 2026.
The investor day is scheduled for October 29, 2026.
X4 Pharmaceuticals had a USD 321.2 million market capitalization on October 23, 2026.

XFOR, US98420X2027, Illustration mit AI erstellt.

X4 Pharmaceuticals (ISIN US98420X2027) chairman Adam Craig purchased 4,600 shares on October 16, 2026, at an average USD 2.58 per share, according to MarketBeat. The purchase increased his direct holding to 333,251 shares and gives investors a fresh insider transaction ahead of the company's next clinical update.

Three financing and trial steps

The company disclosed three dated developments in October. On October 1, 2026, X4 granted inducement options covering 80,000 shares at an exercise price of USD 2.90. On October 8, 2026, it secured a senior secured term loan facility of up to USD 150 million, including an initial USD 80 million tranche, as reported by GlobeNewswire. The October 16 purchase by Craig was the latest of the three events.

What does the financing change?

The new facility replaces X4's previous loan agreement and gives the company access to USD 70 million more subject to lender approval. The initial tranche was used partly to repay USD 75 million of principal under the prior facility, while the agreement provides a 48-month maturity, according to GlobeNewswire. For investors, the key comparison is between the USD 150 million facility size and the USD 80 million already funded.

Upcoming dates for mavorixafor

X4 will host a virtual investor day on October 29, 2026, from 10:00 a.m. to 12:00 p.m. ET. Management plans to discuss the Phase 3 4WARD trial, a planned Phase 2 study and the commercial opportunity for mavorixafor, according to GlobeNewswire. The company expects to complete 4WARD enrollment by year-end 2026 and report topline data in the first half of 2028.

Nasdaq valuation and clinical runway

X4 Pharmaceuticals was trading at USD 3.24 on Nasdaq on October 23, 2026 at 4:00 p.m. ET. Its market capitalization was USD 321.2 million on that date, while the 52-week range was USD 2.43 to USD 4.83. The financing, insider purchase and October 29 event place capital access and trial execution at the center of the stock's near-term narrative.